أعرض في EDS

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

التفاصيل البيبلوغرافية
العنوان:	Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
المؤلفون:	Luis-Emilio Garcia-Perez, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Katie D. Stewart, Katelyn N. Cutts
المصدر:	Quality of Life Research
بيانات النشر:	Springer Science and Business Media LLC, 2021.
سنة النشر:	2021
مصطلحات موضوعية:	Male, medicine.medical_specialty, Type 2 diabetes, Article, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, Route of administration, 0302 clinical medicine, Utility, Internal medicine, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, GLP-1 RA, Glucagon-like peptide 1 receptor, Aged, business.industry, 030503 health policy & services, Public health, Semaglutide, Treatment process, Public Health, Environmental and Occupational Health, Middle Aged, medicine.disease, Treatment process utility, Diabetes Mellitus, Type 2, Quality of Life, Glucagon-like peptide-1 receptor agonist, Female, Dulaglutide, 0305 other medical science, business, Dose Frequency, (4–6): Health state utility, medicine.drug
الوصف:	Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D). Methods Participants with T2D in the UK reported preferences and valued four health state vignettes in time trade-off utility interviews. The vignettes had identical descriptions of T2D but differed in treatment process: (1) daily simple oral treatment (tablets without administration requirements), (2) daily oral semaglutide (with administration requirements per product label), (3) weekly dulaglutide injection, (4) weekly semaglutide injection. Results Interviews were completed by 201 participants (52.7% male; mean age = 58.7). Preferences between treatment processes varied widely. Mean utilities were 0.890 for simple oral, 0.880 for oral semaglutide, 0.878 for dulaglutide injection, and 0.859 for semaglutide injection (with higher scores indicating greater preference). All pairwise comparisons found statistically significant differences between utilities (p Conclusions Results suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient preferences for treatment process when selecting medications for patients in clinical settings.
تدمد:	1573-2649 0962-9343
الوصول الحر:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c15aa003fafb860c63db79688923fe1Test https://doi.org/10.1007/s11136-021-02808-2Test
حقوق:	OPEN
رقم الانضمام:	edsair.doi.dedup.....6c15aa003fafb860c63db79688923fe1
قاعدة البيانات:	OpenAIRE

ResultId	1
Header	edsair OpenAIRE edsair.doi.dedup.....6c15aa003fafb860c63db79688923fe1 884 3 unknown 883.58740234375
PLink	https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6c15aa003fafb860c63db79688923fe1&custid=s6537998&authtype=sso
FullText	Array ( [Availability] => 0 )
Items	Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes ) Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Luis-Emilio+Garcia-Perez%22">Luis-Emilio Garcia-Perez</searchLink><br /><searchLink fieldCode="AR" term="%22Louis+S%2E+Matza%22">Louis S. Matza</searchLink><br /><searchLink fieldCode="AR" term="%22Kirsi+Norrbacka%22">Kirsi Norrbacka</searchLink><br /><searchLink fieldCode="AR" term="%22Kristina+S%2E+Boye%22">Kristina S. Boye</searchLink><br /><searchLink fieldCode="AR" term="%22Katie+D%2E+Stewart%22">Katie D. Stewart</searchLink><br /><searchLink fieldCode="AR" term="%22Katelyn+N%2E+Cutts%22">Katelyn N. Cutts</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Quality of Life Research ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Springer Science and Business Media LLC, 2021. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Type+2+diabetes%22">Type 2 diabetes</searchLink><br /><searchLink fieldCode="DE" term="%22Article%22">Article</searchLink><br /><searchLink fieldCode="DE" term="%22Glucagon-Like+Peptide-1+Receptor%22">Glucagon-Like Peptide-1 Receptor</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Route+of+administration%22">Route of administration</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Utility%22">Utility</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Hypoglycemic+Agents%22">Hypoglycemic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22030212+general+%26+internal+medicine%22">030212 general & internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22GLP-1+RA%22">GLP-1 RA</searchLink><br /><searchLink fieldCode="DE" term="%22Glucagon-like+peptide+1+receptor%22">Glucagon-like peptide 1 receptor</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22030503+health+policy+%26+services%22">030503 health policy & services</searchLink><br /><searchLink fieldCode="DE" term="%22Public+health%22">Public health</searchLink><br /><searchLink fieldCode="DE" term="%22Semaglutide%22">Semaglutide</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+process%22">Treatment process</searchLink><br /><searchLink fieldCode="DE" term="%22Public+Health%2C+Environmental+and+Occupational+Health%22">Public Health, Environmental and Occupational Health</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+process+utility%22">Treatment process utility</searchLink><br /><searchLink fieldCode="DE" term="%22Diabetes+Mellitus%2C+Type+2%22">Diabetes Mellitus, Type 2</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+Life%22">Quality of Life</searchLink><br /><searchLink fieldCode="DE" term="%22Glucagon-like+peptide-1+receptor+agonist%22">Glucagon-like peptide-1 receptor agonist</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Dulaglutide%22">Dulaglutide</searchLink><br /><searchLink fieldCode="DE" term="%220305+other+medical+science%22">0305 other medical science</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Dose+Frequency%22">Dose Frequency</searchLink><br /><searchLink fieldCode="DE" term="%22%284–6%29%3A+Health+state+utility%22">(4–6): Health state utility</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D). Methods Participants with T2D in the UK reported preferences and valued four health state vignettes in time trade-off utility interviews. The vignettes had identical descriptions of T2D but differed in treatment process: (1) daily simple oral treatment (tablets without administration requirements), (2) daily oral semaglutide (with administration requirements per product label), (3) weekly dulaglutide injection, (4) weekly semaglutide injection. Results Interviews were completed by 201 participants (52.7% male; mean age = 58.7). Preferences between treatment processes varied widely. Mean utilities were 0.890 for simple oral, 0.880 for oral semaglutide, 0.878 for dulaglutide injection, and 0.859 for semaglutide injection (with higher scores indicating greater preference). All pairwise comparisons found statistically significant differences between utilities (p Conclusions Results suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient preferences for treatment process when selecting medications for patients in clinical settings. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1573-2649<br />0962-9343 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c15aa003fafb860c63db79688923fe1" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c15aa003fafb860c63db79688923fe1</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1007/s11136-021-02808-2" linkWindow="_blank">https://doi.org/10.1007/s11136-021-02808-2</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....6c15aa003fafb860c63db79688923fe1 )
RecordInfo	Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 11 [StartPage] => 2033 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Male [Type] => general ) [1] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [2] => Array ( [SubjectFull] => Type 2 diabetes [Type] => general ) [3] => Array ( [SubjectFull] => Article [Type] => general ) [4] => Array ( [SubjectFull] => Glucagon-Like Peptide-1 Receptor [Type] => general ) [5] => Array ( [SubjectFull] => 03 medical and health sciences [Type] => general ) [6] => Array ( [SubjectFull] => Route of administration [Type] => general ) [7] => Array ( [SubjectFull] => 0302 clinical medicine [Type] => general ) [8] => Array ( [SubjectFull] => Utility [Type] => general ) [9] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [10] => Array ( [SubjectFull] => medicine [Type] => general ) [11] => Array ( [SubjectFull] => Humans [Type] => general ) [12] => Array ( [SubjectFull] => Hypoglycemic Agents [Type] => general ) [13] => Array ( [SubjectFull] => 030212 general & internal medicine [Type] => general ) [14] => Array ( [SubjectFull] => GLP-1 RA [Type] => general ) [15] => Array ( [SubjectFull] => Glucagon-like peptide 1 receptor [Type] => general ) [16] => Array ( [SubjectFull] => Aged [Type] => general ) [17] => Array ( [SubjectFull] => business.industry [Type] => general ) [18] => Array ( [SubjectFull] => 030503 health policy & services [Type] => general ) [19] => Array ( [SubjectFull] => Public health [Type] => general ) [20] => Array ( [SubjectFull] => Semaglutide [Type] => general ) [21] => Array ( [SubjectFull] => Treatment process [Type] => general ) [22] => Array ( [SubjectFull] => Public Health, Environmental and Occupational Health [Type] => general ) [23] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [24] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [25] => Array ( [SubjectFull] => Treatment process utility [Type] => general ) [26] => Array ( [SubjectFull] => Diabetes Mellitus, Type 2 [Type] => general ) [27] => Array ( [SubjectFull] => Quality of Life [Type] => general ) [28] => Array ( [SubjectFull] => Glucagon-like peptide-1 receptor agonist [Type] => general ) [29] => Array ( [SubjectFull] => Female [Type] => general ) [30] => Array ( [SubjectFull] => Dulaglutide [Type] => general ) [31] => Array ( [SubjectFull] => 0305 other medical science [Type] => general ) [32] => Array ( [SubjectFull] => business [Type] => general ) [33] => Array ( [SubjectFull] => Dose Frequency [Type] => general ) [34] => Array ( [SubjectFull] => (4–6): Health state utility [Type] => general ) [35] => Array ( [SubjectFull] => medicine.drug [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Luis-Emilio Garcia-Perez ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Louis S. Matza ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kirsi Norrbacka ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kristina S. Boye ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Katie D. Stewart ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Katelyn N. Cutts ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 22 [M] => 04 [Type] => published [Y] => 2021 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 15732649 ) [1] => Array ( [Type] => issn-print [Value] => 09629343 ) [2] => Array ( [Type] => issn-locals [Value] => edsair ) [3] => Array ( [Type] => issn-locals [Value] => edsairFT ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 30 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Quality of Life Research [Type] => main ) ) ) ) ) ) )
IllustrationInfo